Table 3 Pharmacological agents in development with potential for treating sarcopenia
From: Sarcopenia in daily practice: assessment and management
Mechanism of action | Drug name | Drug Developer | Indication sought | Study phase |
|---|---|---|---|---|
I. Myostatin Antagonists | ||||
 Activin receptor trap | ACE-031 | Acceleron | Duchenne muscular dystrophy | Phase 3 (trial terminated early) |
 Myostatin antibody | REGN-1033 | Regeneron/Sanofi | Sarcopenia | Phase 2 |
| Â | LY-2495655 | Eli Lilly | Hip arthroplasty | Phase 2 |
Elderly Fallers | ||||
Cancer Cachexia | ||||
| Â | PF-06252616 | Pfizer | Inclusion body myositis | Phase 1 |
 Activin receptor inhibitor | Bimagrumab (BMY338) | Novartis | Sarcopenia | Phase 2 and 3 |
Hip fracture | Phase 2 | |||
Cancer and COPD cachexia | Â | |||
II. Selective Androgen Receptor Modulators | Enobasarm (Ostarine) | GTx | Cancer Cachexia | Phase 3 (did not meet primary endpoint) |
III. Skeletal Troponin Activators | Tirasemtiv | Cytokinetics | ALS | Phase 2,3 |
CK-2017357 | Myasthenia Gravis | |||